Skip to content
Screener

Regeneron Pharmaceuticals REGN Q1 2026 earnings

Reported April 29, 2026 · Before market open

Revenue$3.6BBeat by $124.9M
EPS$9.47Beat by $0.56
Revenue estimate$3.5B
EPS estimate$8.91

Next report

Oct 30, 2026 (In 3 weeks)
Revenue estimate$4.5B
EPS estimate$15.99

Financials

Q1 2026

Income statement

See full
Revenue$3.6B+19.0%
Operating income$642.9M+8.7%
Net income$727.2M-10.1%
EPS (diluted)$6.75-7.2%

Balance sheet

See full
Cash & equivalents$3.0B-4.0%
Total debt$2.7B+0.1%
Total equity$31.4B+6.9%
Total assets$40.9B+8.9%

Cash flow

See full
Operating cash flow$1.1B+3.2%
CapEx$230.6M+0.6%
Free cash flow$848.3M+4.0%

Valuation & ratios

Valuation

as of 03/31/26
See full
Market cap$81.68B+17.8%
Enterprise value$81.42B+18.1%
P/E18.5×+3.1×
P/S5.5×+0.6×

Profitability

See full
Operating margin24.3%-2.9pp
Net margin29.6%-2.3pp
FCF margin27.6%+5.5pp

Returns & leverage

See full
Return on equity14.5%-1.4pp
Debt / equity0.1×0.0×
Current ratio3.6×-1.4×

FAQ

When did Regeneron Pharmaceuticals report Q1 2026 earnings?
Regeneron Pharmaceuticals (REGN) reported Q1 2026 earnings on April 29, 2026 before market open.
What were Regeneron Pharmaceuticals's Q1 2026 revenue and EPS?
Regeneron Pharmaceuticals reported revenue of $3.6B and eps of $9.47 for Q1 2026.
Did Regeneron Pharmaceuticals beat estimates in Q1 2026?
Revenue beat the consensus estimate of $3.5B by $124.9M. EPS beat the consensus estimate of $8.91 by $0.56.
How did Regeneron Pharmaceuticals's Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 19.0% from $3.0B a year earlier and eps grew 15.2% from $8.22.
Where can I find Regeneron Pharmaceuticals's Q1 2026 SEC filings?
You can read the 8-K earnings release (0000872589-26-000014) and the 10-Q periodic report (0000872589-26-000016) directly on SEC EDGAR. The filing index links above go to sec.gov.